About Ankyrin repeat domain-containing protein 42
Ankyrin repeat domain-containing protein 42 (ANKRD42) is a protein
from Homo sapiens identified by UniProt accession
Q8N9B4, 389 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Ankyrin repeat domain-containing protein 42 |
| UniProt accession | Q8N9B4 |
| Gene | ANKRD42 |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (14)
Diseases linked to this target (Open Targets).
- chronotype measurement · score 0.06
- brain volume measurement · score 0.02
- pulmonary fibrosis · score 0.01
- neoplasm · score 0.01
- immature platelet fraction · score 0.00
- squamous cell carcinoma · score 0.00
- acute myocardial infarction · score 0.00
- myocardial infarction · score 0.00
- Myocardial Ischemia · score 0.00
- diabetes mellitus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N9B4-F1 | alphafold | PREDICTED | 77.48 | — |
Amino-acid sequence (389 residues)
MPGVANSGPS TSSRETANPC SRKKVHFGSI HDAVRAGDVK QLSEIVCLHW LLWHGADITH VTTRGWTASH IAAIRGQDAC VQALIMNGAN LTAQDDRGCT PLHLAATHGH SFTLQIMLRS GVDPSVTDKR EWRPVHYAAF HGRLGCLQLL VKWGCSIEDV DYNGNLPVHL AAMEGHLHCF KFLVSRMSSA TQVLKAFNDN GENVLDLAQR FFKQNILQFI QGAEYEGKDL EDQETLAFPG HVAAFKGDLG MLKKLVEDGV ININERADNG STPMHKAAGQ GHIECLQWLI KMGADSNITN KAGERPSDVA KRFAHLAAVK LLEELQKYDI DDENEIDEND VKYFIRHGVE GSTDAKDDLC LSDLDKTDAR RPSKNCRASW SMNDYVEKN
Explore Ankyrin repeat domain-containing protein 42 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets